LifeVantage Completes Successful Human Clinical Trial with New GLP-1 System for Activated Weight Loss* †
LifeVantage (Nasdaq: LFVN) has completed a successful 12-week human clinical trial evaluating its innovative GLP-1 system for weight management. The study, involving 60 participants, assessed the system's impact on weight management, food cravings, and overall well-being. Participants were divided into three groups: product system alone, product system with diet and exercise guidance, and a control group.
Lisa Barnes, VP of Research, Development & Regulatory, expressed confidence in the system's ability to address weight management challenges through natural activation of GLP-1. The results will be shared at Market Connect in Kansas City, October 11-12, 2024, where the system will be revealed. CEO Steve Fife emphasized the company's commitment to delivering products that activate the body's natural processes. This trial, along with a recently completed in vitro study, marks a significant milestone in LifeVantage's efforts to expand its portfolio of activation products supporting cellular health.
LifeVantage (Nasdaq: LFVN) ha completato con successo un trial clinico umano della durata di 12 settimane per valutare il suo innovativo sistema GLP-1 per la gestione del peso. Lo studio, che ha coinvolto 60 partecipanti, ha valutato l'impatto del sistema sulla gestione del peso, sui desideri alimentari e sul benessere generale. I partecipanti sono stati divisi in tre gruppi: solo sistema di prodotto, sistema di prodotto con guida dietetica e di esercizio, e un gruppo di controllo.
Lisa Barnes, VP di Ricerca, Sviluppo e Regolamentazione, ha espresso fiducia nella capacità del sistema di affrontare le sfide della gestione del peso attraverso l'attivazione naturale del GLP-1. I risultati saranno presentati a Market Connect a Kansas City, dall'11 al 12 ottobre 2024, dove il sistema sarà svelato. Il CEO Steve Fife ha sottolineato l'impegno dell'azienda a fornire prodotti che attivano i processi naturali del corpo. Questo trial, insieme a uno studio in vitro recentemente completato, rappresenta un importante traguardo negli sforzi di LifeVantage per ampliare il suo portafoglio di prodotti di attivazione a sostegno della salute cellulare.
LifeVantage (Nasdaq: LFVN) ha completado con éxito un ensayo clínico humano de 12 semanas que evalúa su innovador sistema GLP-1 para el manejo del peso. El estudio, que involucró a 60 participantes, evaluó el impacto del sistema en el manejo del peso, los antojos de alimentos y el bienestar general. Los participantes se dividieron en tres grupos: solo el sistema de producto, el sistema de producto con orientación dietética y de ejercicio, y un grupo de control.
Lisa Barnes, VP de Investigación, Desarrollo y Regulación, expresó confianza en la capacidad del sistema para abordar los desafíos del manejo del peso a través de la activación natural de GLP-1. Los resultados se compartirán en Market Connect en Kansas City, del 11 al 12 de octubre de 2024, donde se revelará el sistema. El CEO Steve Fife enfatizó el compromiso de la empresa de ofrecer productos que activen los procesos naturales del cuerpo. Este ensayo, junto con un estudio in vitro recientemente completado, marca un hito significativo en los esfuerzos de LifeVantage por expandir su cartera de productos de activación que apoyan la salud celular.
라이프반타지 (Nasdaq: LFVN)가 혁신적인 체중 관리용 GLP-1 시스템을 평가하는 12주간의 성공적인 인간 임상 시험을 완료했습니다. 이 연구는 60명의 참가자를 대상으로 하였으며, 시스템의 체중 관리, 음식 갈망 및 전반적인 웰빙에 미치는 영향을 평가했습니다. 참가자들은 세 그룹으로 나뉘었으며: 제품 시스템 단독, 다이어트 및 운동 지침이 포함된 제품 시스템, 대조 그룹입니다.
연구개발 및 규제 담당 부사장인 리사 반스는 시스템이 GLP-1의 자연적 활성화를 통해 체중 관리 문제를 해결할 수 있다고 확신을 표명했습니다. 결과는 2024년 10월 11일부터 12일까지 캔자스 시티에서 열리는 마켓 커넥트에서 공유될 예정이며, 이곳에서 시스템이 공개됩니다. CEO 스티브 피프는 자연적인 신체 과정 활성화를 통해 제품을 제공하겠다는 회사의 약속을 강조했습니다. 이번 시험과 최근 완료된 인비트로 연구는 세포 건강을 지원하는 활성화 제품 포트폴리오를 확장하려는 라이프반타지의 중요한 이정표를 의미합니다.
LifeVantage (Nasdaq: LFVN) a achevé avec succès un essai clinique humain de 12 semaines évaluant son innovant système GLP-1 pour la gestion du poids. L'étude, impliquant 60 participants, a évalué l'impact du système sur la gestion du poids, les envies alimentaires et le bien-être général. Les participants ont été répartis en trois groupes : système de produit seul, système de produit avec conseils diététiques et d'exercice, et un groupe témoin.
Lisa Barnes, VP de la Recherche, du Développement et de la Réglementation, a exprimé sa confiance dans la capacité du système à relever les défis de la gestion du poids grâce à l'activation naturelle du GLP-1. Les résultats seront partagés lors de Market Connect à Kansas City, du 11 au 12 octobre 2024, où le système sera révélé. Le PDG Steve Fife a souligné l'engagement de l'entreprise à fournir des produits qui activent les processus naturels du corps. Cet essai, avec une étude in vitro récemment terminée, marque une étape importante dans les efforts de LifeVantage pour élargir son portefeuille de produits d'activation soutenant la santé cellulaire.
LifeVantage (Nasdaq: LFVN) hat eine erfolgreiche 12-wöchige klinische Studie am Menschen abgeschlossen, um sein innovatives GLP-1-System zur Gewichtsregulation zu bewerten. Die Studie, an der 60 Teilnehmer teilnahmen, untersuchte die Auswirkungen des Systems auf die Gewichtsregulation, Essensgelüste und das allgemeine Wohlbefinden. Die Teilnehmer wurden in drei Gruppen unterteilt: Produkt-System allein, Produkt-System mit Diät- und Bewegungshinweisen und eine Kontrollgruppe.
Lisa Barnes, VP für Forschung, Entwicklung und Regulierung, äußerte Vertrauen in die Fähigkeit des Systems, Herausforderungen im Bereich der Gewichtsregulation durch natürliche Aktivierung von GLP-1 anzugehen. Die Ergebnisse werden vom 11. bis 12. Oktober 2024 beim Market Connect in Kansas City präsentiert, wo das System vorgestellt wird. CEO Steve Fife betonte das Engagement des Unternehmens, Produkte anzubieten, die die natürlichen Prozesse des Körpers aktivieren. Diese Studie, zusammen mit einer kürzlich abgeschlossenen In-vitro-Studie, markiert einen bedeutenden Meilenstein in den Bemühungen von LifeVantage, sein Portfolio an Aktivierungsprodukten zur Unterstützung der Zellgesundheit zu erweitern.
- Successful completion of a 12-week human clinical trial for the GLP-1 weight management system
- Positive preliminary results indicating the system's efficacy in activating GLP-1 for weight management
- Expansion of product portfolio in the growing weight management market
- None.
Insights
The completion of LifeVantage's human clinical trial for their GLP-1 system is a significant development in the weight management sector. The 12-week study involving 60 participants across three groups provides a solid foundation for evaluating the system's efficacy. Key points to consider:
- The trial's focus on activating GLP-1 naturally aligns with current trends in weight management, potentially offering a competitive edge in a market dominated by injectable GLP-1 agonists.
- The two-product system's approach to weight management, food cravings and overall well-being addresses multiple aspects of metabolic health, which could appeal to a broader consumer base.
- The company's emphasis on "activating optimal health processes at the cellular level" suggests a holistic approach to weight management, which may differentiate it from traditional diet products.
However, investors should note that full results are yet to be disclosed and the true impact on LifeVantage's market position will depend on the strength of these findings and subsequent product launch success.
This clinical trial completion marks a potential inflection point for LifeVantage (LFVN). Key financial implications include:
- Expansion into the lucrative weight management market, which is projected to reach
$405.4 billion globally by 2030, could significantly boost revenue streams. - The timing of the product reveal at the October Market Connect event may catalyze short-term stock movement, especially if the results are compelling.
- With a current market cap of
$138.7 million , successful entry into this market could lead to substantial growth opportunities. - The company's investment in R&D for this product system demonstrates a commitment to innovation, which could attract investor interest.
However, the impact on financials will ultimately depend on the product's efficacy, pricing strategy and market acceptance. Investors should watch for detailed trial results and initial sales figures post-launch to gauge the potential long-term impact on LifeVantage's financial performance.
Breakthrough study paves the way for innovative, science-driven weight management solutions designed to activate optimal health at the cellular level*
SALT LAKE CITY, Sept. 26, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, has completed its randomized, 12-week human clinical trial evaluating the efficacy of its innovative GLP-1 system for weight management. The study was conducted to explore the system’s potential to activate GLP-1 in users and support their health goals. * †
The clinical trial, which began in mid-June 2024, involved 60 participants and was designed to assess the impact the innovative two-product system has on weight management, food cravings, and overall well-being, among other factors. * †
Participants were divided into three groups to evaluate the system's effects under different conditions, comparing the product system alone, the product system combined with diet and exercise guidance, and a control group, over the course of the three-month period.
“We are thrilled to have completed this key phase of our research and for the results we are seeing with these products,” said Lisa Barnes, Vice President of Research, Development & Regulatory at LifeVantage. “The data from this human clinical shows a remarkable ability of our unique two-product system to address weight management challenges through the natural activation of the health-supporting hormone, GLP-1. We remain confident that our science-backed approach will provide innovative solutions to meet the growing demand for effective, naturally supported weight management.” * †
Results of the human clinical trial will be shared with LifeVantage Consultants at Market Connect in Kansas City, October 11-12, 2024, where the system will be revealed.
“We continually invest in research to make sure we always deliver on our promise of having products that activate the body’s natural processes, restoring health where it matters most,” said Steve Fife, President and CEO. “Our team has worked tirelessly for over a year on this system to ensure our Consultants can approach this market with confidence in the efficacy of these products. There has never been a better time to be a LifeVantage Consultant and build a business with us. I couldn’t be more proud of what we are building together.”*
The completion of this human clinical trial, as well as the completion of the in vitro study announced earlier this month, represents a significant milestone in company efforts to expand its portfolio of activation products designed to support health at the cellular level. The soon to be released product system activates production of the GLP-1 hormone to not only support weight management, but also metabolic health and long-term well-being. * †
For further information about LifeVantage and Activation, please visit LifeVantage.com.
About LifeVantage Corporation
LifeVantage Corporation (Nasdaq: LFVN), the activation company, is a pioneer in nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. The Company engages in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and probiotics, weight management, and skin and hair care products. The Company’s line of scientifically-validated dietary supplements includes its flagship Protandim® family of products, LifeVantage® Omega+, ProBio, IC Bright®, Daily Wellness, Rise AM, Reset PM, and D3+ dietary supplements, the TrueScience® line of skin and hair care products and Liquid Collagen. The Company also markets and sells Petandim®, its companion pet supplement formulated to combat oxidative stress in dogs and Axio®, its nootropic energy drink mixes. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.*
Public Relations Contact:
Jennifer Rumble, CerconeBrownCompany
(704) 923-6378
jrumble@cerconebrown.com
Investor Relations Contact:
Reed Anderson, ICR
(646) 277-1260
reed.anderson@icrinc.com
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
†Results may vary. This product should be used in conjunction with a healthy diet and regular exercise. Consult with a healthcare provider before starting any weight loss program.
FAQ
What were the results of LifeVantage's (LFVN) GLP-1 system clinical trial?
How many participants were involved in LifeVantage's (LFVN) GLP-1 system clinical trial?
When will LifeVantage (LFVN) reveal its new GLP-1 system for weight management?
What is the purpose of LifeVantage's (LFVN) new GLP-1 system?
